China SXT Pharmaceuticals, Inc. (SXTC): Cash & Equivalents
$28.18M
As of 2026-03-31
+17.5%
3-year compound annual growth
+16.1%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $28.18M | +55.7% | 2026-07-01, Balance as of period end |
| 2025-03-31 | $18.10M | +49.9% | 2026-07-01, Balance as of period end |
| 2024-03-31 | $12.07M | -30.5% | 2025-07-31, Balance as of period end |
| 2023-03-31 | $17.37M | n/a | 2024-08-13, Balance as of period end |
| No annual figure between 2021-03-31 and 2023-03-31. | |||
| 2021-03-31 | $13.36M | +83.3% | 2021-08-13, Balance as of period end |
| 2020-03-31 | $7.29M | -21.6% | 2021-08-13, Balance as of period end |
| 2019-03-31 | $9.29M | n/c | 2021-08-13, Balance as of period end |
| 2018-03-31 | $657.8K | n/c | 2020-07-31, Balance as of period end |
| 2017-03-31 | $65.6K | n/a | 2019-08-15, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $28.18M | +55.7% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $19.87M | +39.8% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $4.66M | -75.8% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $24.71M | +57.4% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $30.79M | -54.1% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $405.0K | -66.2% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $1.51M | -9.0% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $54.19M | -5.6% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $1.8K | -16.3% |
Compare SXTC, NEUP, LGVN, DARE side by side · Screen every company in Pharmaceutical Preparations ↗